RFA-DK-23-014: NIDDK Catalyst Award (DP1 Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2023.
National Institutes of Health offered grants of up to $500,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on September 28, 2023.
From the official notice on Grants.gov, last changed June 15, 2023. Checked November 7, 2026.
- Award ceiling$500,000
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeDP1
- Clinical trialsNot allowed
- Funded byNIDDK
- Median yearly award$754,400
- Typical project length4.5 years
- DP1, NIH Director's Pioneer Award. Support for an exceptionally creative scientist's high-risk, high-impact ideas. Other open DP1 notices.
Projects funded under RFA-DK-23-014 were run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, 8 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-DK-23-014 in the NIH Guide.
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| RFA-DK-26-006 | December 18, 2024 | Closed July 18, 2025 | Closed |
Key dates
| Posted | June 15, 2023 |
|---|---|
| Deadline | September 28, 2023 |
| Archived by Grants.gov | November 3, 2023 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $754,400; it allows up to $500,000 per award.
- Most of the program's money (70% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The NIDDK Catalyst Award is designed to complement NIDDK's traditional, investigator-initiated grant programs by supporting individual scientists who propose pioneering and transformational studies in topic areas of interest to NIDDK's Division of Diabetes, Endocrinology and Metabolic Diseases, and to NIDDK's Division of Digestive Diseases and Nutrition. Applications should be focused on major scientific challenges, and have the potential to produce an unusually high impact on diseases and conditions that are central to the mission of these two divisions within NIDDK. To be considered responsive to this initiative, the proposed research should reflect new and novel scientific directions that are distinct from concepts and approaches being pursued in the investigators research program or elsewhere.
Funded under RFA-DK-23-014 so far
NIH funded 8 projects under RFA-DK-23-014 in fiscal 2024 to 2026, at 7 institutions. The median yearly award was $754,400.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Beyond insulin: Next-generation modulators of insulin receptor for glycemic control | Stanford University | 2026 | $772,383 |
| Memory in the enteric nervous system | Stanford University | 2026 | $752,304 |
| Decoding endocrine and paracrine communication through mammokines | Icahn School of Medicine at Mount Sinai | 2026 | $800,000 |
| Elucidating chronic liver disease pathways using somatic genetics | UT Southwestern Medical Center | 2026 | $754,400 |
| Reprogramming intestinal immunity in preterm neonates to prevent and cure necrotizing enterocolitis | Univ of North Carolina Chapel Hill | 2026 | $725,184 |
| High-dimensional chemical targeting of multiple neuron types to regulate energy balance | Beth Israel Deaconess Medical Center | 2026 | $800,000 |
| Extracellular vesicle-dependent RNA signaling in metabolism | University of Colorado | 2025 | $374,847 |
| A Systems Approach for Elucidating Genetic Determinants of Human Brown Adipose Tissue Function | Rockefeller University | 2024 | $604,853 |
Who has won Diabetes, Digestive, and Kidney Diseases Extramural Research grants before
From fiscal 2021 to 2025, Diabetes, Digestive, and Kidney Diseases Extramural Research (93.847) awarded $9.6 billion across 7,877 grant awards, an average of $1.2 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Regents of the University of Michigan | Michigan | 273 | $345 million |
| The Trustees of the University of Pennsylvania | Pennsylvania | 187 | $272 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 209 | $238 million |
| The Washington University | Missouri | 187 | $227 million |
| The Regents of the University of California, San Francisco | California | 176 | $208 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-DK-23-014 still open?
No. It closed on September 28, 2023.
Who can apply for NIDDK Catalyst Award (DP1 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for NIDDK Catalyst Award (DP1 Clinical Trial Not Allowed)?
Closed September 28, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $500,000 each.
Who has been funded under RFA-DK-23-014?
NIH RePORTER lists 8 projects funded under RFA-DK-23-014 in fiscal 2024 to 2026, at 7 institutions. The most were at Stanford University, Icahn School of Medicine at Mount Sinai, UT Southwestern Medical Center.
Who has won Diabetes, Digestive, and Kidney Diseases Extramural Research grants before?
The largest recipients over five fiscal years were Regents of the University of Michigan, The Trustees of the University of Pennsylvania, University of Pittsburgh - of the Commonwealth System of Higher Education. The program made 7,877 awards worth $9.6 billion in that time.
Similar open grants
- Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
- NIH Director's Pioneer Award (DP1 Clinical Trial Optional)
- Avant Garde/Avenir Awards for Investigators Conducting High Risk/High Reward Research on HIV and Substance Use (or Substance Use Disorders) (DP1 Clinical Trial Optional)
- Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)